Shenzhen Salubris Pharmaceuticals officially initiated its application for a Hong Kong listing on Thursday. While the company—which specializes in innovative drugs and medical devices—remains tight-lipped regarding the specific size or timeline of the offering, its recent financial health offers a baseline for investors. The firm reported a 4% increase in net profit for the first half of the year, reaching 390.5 million yuan, or US$58.1 million.
In section Market Quotes
Chinese Pharma Firms Seek Hong Kong Capital
Two mainland pharmaceutical players are turning to Hong Kong’s financial hub to fuel their expansion, signaling a broader shift as high-tech firms increasingly tap the city’s exchange. The move follows a period of aggressive growth in IPO fundraising, which has more than doubled in the city over the past year.
Simultaneously, Genscript Biotech is pursuing a carve-out of its subsidiary, Probio Technology. This spin-off will house the group’s biologics and advanced therapy contract services. The decision follows a recent surge in demand for the company’s AI-enabled drug discovery tools. These entries bolster a market that saw IPO fundraising hit 328.21 billion Hong Kong dollars—roughly US$41.86 billion—during the first seven months of 2026, marking a robust recovery for the exchange.
Comments (0)
No comments yet. Be the first!